Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Metabolism, Alcohol & Toxicity
1
Bristol Myers Squibb: NASH: An evolution in treatment response tools - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
